Find your next paid study

Laminar PharmaceuticalsNCT04299191

International Pleuropulmonary Blastoma/DICER1 Registry (for PPB, DICER1 and Associated Conditions)

Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm of the lung presenting in early childhood. Type I PPB is a purely cystic lesion, Type II is a parti…

Pleuropulmonary BlastomaSertoli-Leydig Cell TumorDICER1 Syndrome+16 more

Children's Hospitals and Clinics of MinnesotaNCT03382158

~$10 – $750

Non Hodgkin LymphomaSolid Tumor

An Open-Label, First-in-Human Phase 1/2, Dose-Escalation and Dose-Expansion/ Combination Therapy Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SB-4826 as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas and in Combination With Rituximab in Adult Participants With Non-Hodgkin Lymphomas

The goal of this clinical trial is to learn what dose of the drug SB-4826 can be given safely in patients with solid tumors and non-Hodgkin lymphomas. This dru…

University of California, San DiegoNCT07222631

~$10 – $6,250

Metastatic CancerUnresectable Solid Tumor

Phase 1 Multi-cohort Evaluation of [18F]CSB-321 PET Imaging in Participants Receiving Immunotherapy for the Treatment of Cancer

Single-center with the option to expand to multi-center, international, open label, non-randomized, multiple-dose, multi-cohort study, in participants with met…

Cytosite Biopharma Inc.NCT07057349

Solid Tumor, AdultCarcinoma, Ovarian EpithelialFallopian Tube Neoplasms+3 more

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety a…

Bio-Path Holdings, Inc.NCT04196257

Genetics of Appendix Cancer: The GAP Study

The GAP Study is a prospective cohort study designed to comprehensively investigate genetic variations that may contribute to cancer development among individu…

Appendix CancerAppendiceal CancerAppendiceal Neoplasms+12 more

Andreana Holowatyj, PhD, MSCINCT05734430

~$10 – $1,125

Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors. Then t…

Solid Tumor, Adult

Virginia Commonwealth UniversityNCT03919292

~$10 – $6,250

Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+10 more

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pha…

858 Therapeutics, Inc.NCT06395519

Phase 2

A Phase II Study of ASTX727 in Patients With PRC2 Loss Malignant Peripheral Nerve Sheath Tumor (MPNST)

The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a comb…

Malignant Peripheral Nerve Sheath Tumors (MPNST)

Memorial Sloan Kettering Cancer CenterNCT04872543

~$10 – $6,250

Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor+5 more

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conduct…

Frontier Medicines CorporationNCT06244771

Solid TumorMET Alteration

A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations

The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with so…

Pierre Fabre MedicamentNCT06669117

~$10 – $7,500

Locally Advanced Solid TumorMetastatic Solid Tumor

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE2016, an Allogeneic Anti-EGFR Conjugated Gamma Delta T Cell (gdT) Therapy in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally …